Literature DB >> 19562004

Rosacea: a review.

Brittney Culp1, Noah Scheinfeld.   

Abstract

Rosacea is a chronic inflammatory condition of the facial skin affecting the blood vessels and pilosebaceous units. Rosacea is more common in persons of northern and western European descent with a fair complexion, but it can affect skin of any color. Although symptoms may wax and wane during the short term, rosacea can progress with time. Patients usually present with complaints of flushing and blushing and sensitive skin, and their skin may be especially irritated by topical preparations. Rosacea has a variety of triggers; however, they may be unnoticed by the patient.Standard treatments approved by the FDA include azelaic acid, topical metronidazole, and oral tetracyclines, in particular minocycline and doxycycline. Other topical treatments include topical clindamycin, subantimicrobial-dose doxycycline, and sulfur products. Azithromycin and controlled-release minocycline are possible options for treating rosacea, but the FDA has not approved either agent for this indication.

Entities:  

Year:  2009        PMID: 19562004      PMCID: PMC2700634     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  38 in total

1.  Low-dose doxycycline (Oracea) for rosacea.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2007-01-15       Impact factor: 1.909

2.  Allergic contact dermatitis to topical metronidazole - 3 cases.

Authors:  Jakob Torp Madsen; Jens Thormann; Stefan Kerre; Klaus E Andersen; An Goossens
Journal:  Contact Dermatitis       Date:  2007-06       Impact factor: 6.600

Review 3.  Update on rosacea and anti-inflammatory-dose doxycycline.

Authors:  Brian Berman; Oliver A Perez; Deborah Zell
Journal:  Drugs Today (Barc)       Date:  2007-01       Impact factor: 2.245

Review 4.  Interventions for rosacea.

Authors:  E J van Zuuren; M A Graber; S Hollis; M Chaudhry; A K Gupta; M Gover
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

5.  Recalcitrant rosacea successfully treated with multiplexed pulsed dye laser.

Authors:  April A Larson; Mitchel P Goldman
Journal:  J Drugs Dermatol       Date:  2007-08       Impact factor: 2.114

Review 6.  Acne in ethnic skin: special considerations for therapy.

Authors:  Valerie D Callender
Journal:  Dermatol Ther       Date:  2004       Impact factor: 2.851

7.  Rosacea: a clinicopathological approach.

Authors:  Kyriaki Aroni; Eugenia Tsagroni; Andreas C Lazaris; Efstratios Patsouris; Emmanouil Agapitos
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

Review 8.  Topical therapies for rosacea.

Authors:  Jennie B Nally; Diane S Berson
Journal:  J Drugs Dermatol       Date:  2006-01       Impact factor: 2.114

Review 9.  The management of rosacea.

Authors:  Alfredo Rebora
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

10.  A clinical and histopathologic study of granulomatous rosacea.

Authors:  K F Helm; J Menz; L E Gibson; C H Dicken
Journal:  J Am Acad Dermatol       Date:  1991-12       Impact factor: 11.527

View more
  14 in total

Review 1.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 2.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.

Authors:  Mark S Milner; Kenneth A Beckman; Jodi I Luchs; Quentin B Allen; Richard M Awdeh; John Berdahl; Thomas S Boland; Carlos Buznego; Joseph P Gira; Damien F Goldberg; David Goldman; Raj K Goyal; Mitchell A Jackson; James Katz; Terry Kim; Parag A Majmudar; Ranjan P Malhotra; Marguerite B McDonald; Rajesh K Rajpal; Tal Raviv; Sheri Rowen; Neda Shamie; Jonathan D Solomon; Karl Stonecipher; Shachar Tauber; William Trattler; Keith A Walter; George O Waring; Robert J Weinstock; William F Wiley; Elizabeth Yeu
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

3.  Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea.

Authors:  Todd Williamson; Rajesh Kamalakar; Augustina Ogbonnaya; Erin A Zagadailov; Michael Eaddy; Charlie Kreilick
Journal:  Am Health Drug Benefits       Date:  2017-05

4.  Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea.

Authors:  Ag Gravina; A Federico; E Ruocco; A Lo Schiavo; M Masarone; C Tuccillo; F Peccerillo; A Miranda; L Romano; C de Sio; I de Sio; M Persico; V Ruocco; G Riegler; C Loguercio; M Romano
Journal:  United European Gastroenterol J       Date:  2015-02       Impact factor: 4.623

Review 5.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

6.  Unusual features of rosacea in saudi females with dark skin.

Authors:  Amal Omar Al Balbeesi; Mona R Halawani
Journal:  Ochsner J       Date:  2014

7.  Rosacea Patient Perspectives on Homeopathic and Over-the-counter Therapies.

Authors:  Hossein Alinia; Lucy Lan; Sandy Kuo; Karen E Huang; Sarah L Taylor; Steven R Feldman
Journal:  J Clin Aesthet Dermatol       Date:  2015-10

8.  Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study.

Authors:  Todd Williamson; Wendy Y Cheng; Nora McCormick; Francis Vekeman
Journal:  Am Health Drug Benefits       Date:  2018-04

9.  Preliminary open-label clinical evaluation of the soothing and reepithelialization properties of a novel topical formulation for rosacea.

Authors:  Adele Sparavigna; Beatrice Tenconi; Ileana De Ponti
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-10-24

10.  Evaluation of Demodex folliculorum as a Risk Factor for the Diagnosis of Rosacea In Skin Biopsies. Mexico's General Hospital (1975-2010).

Authors:  Jose M Ríos-Yuil; Patricia Mercadillo-Perez
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.